391 related articles for article (PubMed ID: 36239925)
1. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Miller JJ; Gonzalez Castro LN; McBrayer S; Weller M; Cloughesy T; Portnow J; Andronesi O; Barnholtz-Sloan JS; Baumert BG; Berger MS; Bi WL; Bindra R; Cahill DP; Chang SM; Costello JF; Horbinski C; Huang RY; Jenkins RB; Ligon KL; Mellinghoff IK; Nabors LB; Platten M; Reardon DA; Shi DD; Schiff D; Wick W; Yan H; von Deimling A; van den Bent M; Kaelin WG; Wen PY
Neuro Oncol; 2023 Jan; 25(1):4-25. PubMed ID: 36239925
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Wen PY; Weller M; Lee EQ; Alexander BM; Barnholtz-Sloan JS; Barthel FP; Batchelor TT; Bindra RS; Chang SM; Chiocca EA; Cloughesy TF; DeGroot JF; Galanis E; Gilbert MR; Hegi ME; Horbinski C; Huang RY; Lassman AB; Le Rhun E; Lim M; Mehta MP; Mellinghoff IK; Minniti G; Nathanson D; Platten M; Preusser M; Roth P; Sanson M; Schiff D; Short SC; Taphoorn MJB; Tonn JC; Tsang J; Verhaak RGW; von Deimling A; Wick W; Zadeh G; Reardon DA; Aldape KD; van den Bent MJ
Neuro Oncol; 2020 Aug; 22(8):1073-1113. PubMed ID: 32328653
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
[TBL] [Abstract][Full Text] [Related]
5. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
Andronesi OC; Loebel F; Bogner W; Marjańska M; Vander Heiden MG; Iafrate AJ; Dietrich J; Batchelor TT; Gerstner ER; Kaelin WG; Chi AS; Rosen BR; Cahill DP
Clin Cancer Res; 2016 Apr; 22(7):1632-41. PubMed ID: 26534967
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
7. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.
Schiff D; Van den Bent M; Vogelbaum MA; Wick W; Miller CR; Taphoorn M; Pope W; Brown PD; Platten M; Jalali R; Armstrong T; Wen PY
Neuro Oncol; 2019 Jul; 21(7):837-853. PubMed ID: 30753579
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Miller JJ; Shih HA; Andronesi OC; Cahill DP
Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
[TBL] [Abstract][Full Text] [Related]
9. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
[TBL] [Abstract][Full Text] [Related]
10. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
Friedrich M; Bunse L; Wick W; Platten M
Curr Opin Oncol; 2018 Nov; 30(6):368-374. PubMed ID: 30102604
[TBL] [Abstract][Full Text] [Related]
11. Targeting IDH-Mutant Glioma.
Miller JJ
Neurotherapeutics; 2022 Oct; 19(6):1724-1732. PubMed ID: 35476295
[TBL] [Abstract][Full Text] [Related]
12. Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.
Yan D; Li W; Liu Q; Yang K
Front Immunol; 2022; 13():914618. PubMed ID: 35769466
[TBL] [Abstract][Full Text] [Related]
13. Therapies for IDH-Mutant Gliomas.
Alshiekh Nasany R; de la Fuente MI
Curr Neurol Neurosci Rep; 2023 May; 23(5):225-233. PubMed ID: 37060388
[TBL] [Abstract][Full Text] [Related]
14. Glioma-derived mutations in IDH: from mechanism to potential therapy.
Fu Y; Huang R; Du J; Yang R; An N; Liang A
Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
[TBL] [Abstract][Full Text] [Related]
15. In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists.
Kim H; Kim S; Lee HH; Heo H
Korean J Radiol; 2016; 17(5):620-32. PubMed ID: 27587950
[TBL] [Abstract][Full Text] [Related]
16. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
17. Optimize treatment approaches in isocitrate dehydrogenase (IDH) mutant gliomas: open issues.
Rudà R
Neuro Oncol; 2023 Jan; 25(1):26-27. PubMed ID: 36245275
[No Abstract] [Full Text] [Related]
18. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
19. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
Choi C; Raisanen JM; Ganji SK; Zhang S; McNeil SS; An Z; Madan A; Hatanpaa KJ; Vemireddy V; Sheppard CA; Oliver D; Hulsey KM; Tiwari V; Mashimo T; Battiste J; Barnett S; Madden CJ; Patel TR; Pan E; Malloy CR; Mickey BE; Bachoo RM; Maher EA
J Clin Oncol; 2016 Nov; 34(33):4030-4039. PubMed ID: 28248126
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.
Gupta R; Webb-Myers R; Flanagan S; Buckland ME
J Clin Pathol; 2011 Oct; 64(10):835-44. PubMed ID: 21752797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]